NewAmsterdam Pharma Company N.V. (NAMS)
Automate Your Wheel Strategy on NAMS
With Tiblio's Option Bot, you can configure your own wheel strategy including NAMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NAMS
- Rev/Share 0.4059
- Book/Share 6.6942
- PB 2.8278
- Debt/Equity 0.0005
- CurrentRatio 19.9766
- ROIC -0.2439
- MktCap 2125290030.0
- FreeCF/Share -1.1801
- PFCF -15.5088
- PE -11.7329
- Debt/Assets 0.0005
- DivYield 0
- ROE -0.3295
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NAMS | H.C. Wainwright | -- | Buy | -- | $48 | Dec. 30, 2024 |
News
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 132.5% in NewAmsterdam Pharma Company N.V. (NAMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45.
Read More
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company to host R&D day on June 11 th , 2025 in New York City -- –$808.5 million in cash, cash equivalents and marketable securities at March 31, 2025 – NAARDEN, The Netherlands and MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam,” “we,” or the “Company”), a late-stage, clinical biopharmaceutical …
Read More
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) –
Read More
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 --
Read More
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
Read More
About NewAmsterdam Pharma Company N.V. (NAMS)
- IPO Date 2021-02-09
- Website https://www.newamsterdampharma.com
- Industry Biotechnology
- CEO Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Employees 68